These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14713557)

  • 21. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
    Floyd E; Mann P; Long G; Ochoa R
    Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The sequential development of cancer: a morphological perspective.
    Eustis SL
    Toxicol Lett; 1989 Dec; 49(2-3):267-81. PubMed ID: 2690406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detecting and predicting the activity of rodent carcinogens.
    Parry JM
    Mutagenesis; 1994 Jan; 9(1):3-5. PubMed ID: 7911554
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer risk assessment: historical perspectives, current issues, and future directions.
    Velazquez SF; Schoeny R; Rice GE; Cogliano VJ
    Drug Chem Toxicol; 1996 Aug; 19(3):161-85. PubMed ID: 8933022
    [No Abstract]   [Full Text] [Related]  

  • 26. Liver tumor promoters and other mouse liver carcinogens.
    Ward JM; Diwan BA; Lubet RA; Henneman JR; Devor DE
    Prog Clin Biol Res; 1990; 331():85-108. PubMed ID: 2179967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Panel discussion on the application of alternative models to cancer risk assessment.
    Pettit SD
    Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the NTP database to assess the value of rodent carcinogenicity studies for determining human cancer risk.
    Haseman JK
    Drug Metab Rev; 2000 May; 32(2):169-86. PubMed ID: 10774773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotypic properties of preneoplastic rat liver lesions and applications to detection of carcinogens and tumor promoters.
    Williams GM
    Toxicol Pathol; 1998; 26(3):452-3. PubMed ID: 9608653
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of somatic mutations and cell replication kinetics in quantitative cancer risk assessment.
    Moolgavkar SH; Luebeck EG
    Prog Clin Biol Res; 1991; 369():469-79. PubMed ID: 1835095
    [No Abstract]   [Full Text] [Related]  

  • 31. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies.
    Allen DG; Pearse G; Haseman JK; Maronpot RR
    Toxicol Pathol; 2004; 32(4):393-401. PubMed ID: 15307212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Criteria for the evaluation of studies in transgenic models.
    Popp JA
    Toxicol Pathol; 2001; 29 Suppl():20-3. PubMed ID: 11695558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Researchers exploring faster alternatives to 2-year test for carcinogenicity.
    Schmidt C
    J Natl Cancer Inst; 2006 Feb; 98(4):228-30. PubMed ID: 16478737
    [No Abstract]   [Full Text] [Related]  

  • 34. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
    Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
    Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Animal carcinogenicity studies: implications for the REACH system.
    Knight A; Bailey J; Balcombe J
    Altern Lab Anim; 2006 Mar; 34 Suppl 1():139-47. PubMed ID: 16555967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009).
    Friedrich A; Olejniczak K
    Regul Toxicol Pharmacol; 2011 Jul; 60(2):225-48. PubMed ID: 21513764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the toxicity forecasting capability of EPA's ToxCast Phase I data: can ToxCast in vitro assays predict carcinogenicity?
    Benigni R
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2013; 31(3):201-12. PubMed ID: 24024519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies.
    McConnell EE; Solleveld HA; Swenberg JA; Boorman GA
    J Natl Cancer Inst; 1986 Feb; 76(2):283-9. PubMed ID: 3456066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for the identification of rodent carcinogens by in vitro short-term tests.
    Zeiger E
    Prog Clin Biol Res; 1990; 340D():261-71. PubMed ID: 2371299
    [No Abstract]   [Full Text] [Related]  

  • 40. High dose levels are not necessary in rodent studies to detect human carcinogens.
    Monro A; Davies TS
    Cancer Lett; 1993 Dec; 75(3):183-94. PubMed ID: 8313353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.